CAICaris Life Sciences Inc.
$18.47
$0.61
(3.42%)
Closed $18.47
$0.00
(0.00%)
After Hours
EarningsAug 12
Mkt Cap$5.22B
Vol2.4M
Fundamentals
53
Neutral Sentiment
How do you feel about CAI?
Caris Life Sciences Announces Dual Listing on NYSE Texas
Caris Life Sciences Announces Dual Listing on NYSE Texas Caris Life Sciences Announces Dual Listing on NYSE Texas PR Newswire IRVING, Texas, June 16, 2026 IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and...
PR Newswire
Caris Life Sciences Authorized Buy Back Up To $100 Mln
(RTTNews) - Caris Life Sciences (CAI), an AI TechBio company, Monday announced that it has been authorized to repurchase up to $100 million of the company's outstanding common stock...
Nasdaq News: Markets
Caris Life Sciences Announces Share Repurchase Program
Caris Life Sciences Announces Share Repurchase Program Caris Life Sciences Announces Share Repurchase Program PR Newswire IRVING, Texas, June 8, 2026 IRVING, Texas, June 8, 2026 /PRNewswire/ -- Caris Life Sciences (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio...
PR Newswire
Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing
Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing PR Newswire IRVING...
PR Newswire
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with...
PR Newswire
Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels
Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels Caris Life...
PR Newswire
Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure BloodBased Testing Authorization
Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure BloodBased Testing Authorization Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure BloodBased Testing Authorization PR Newswire IRVING, Texas, May 8, 2026...
PR Newswire
Caris Life Sciences Q1 Loss Narrows
(RTTNews) - Caris Life Sciences (CAI) on Thursday reported first-quarter results with revenue rising sharply from last year while losses narrowed, driven by strong growth in molecular profiling services...
Nasdaq News: Markets
Caris Life Sciences Reports First Quarter 2026 Financial Results
Caris Life Sciences Reports First Quarter 2026 Financial Results Caris Life Sciences Reports First Quarter 2026 Financial Results PR Newswire IRVING, Texas, May 7, 2026 Revenue growth of 79% driven...
PR Newswire
UBS Group AG Raises Stock Position in Caris Life Sciences, Inc. $CAI
UBS Group AG lifted its stake in shares of Caris Life Sciences, Inc. (NASDAQ:CAI - Free Report) by 825.9% during the fourth quarter, according to the company in its most recent Form 13F filing with...
MarketBeat
<
1
2
...
>